A breakthrough in the treatment of vaccination blood clots has been made by UK scientists.
UK scientists may have made a CORONAVIRUS breakthrough by discovering a potential therapy for blood clotting in the brain after vaccination.
For the vast majority of people, the COVID-19 vaccine is quite safe. However, there have been a few occurrences of blood clotting in the brain on very rare occasions. Cerebral venous thrombosis (CVT) is a type of blood clotting that can cause strokes and even death.
A study of people who had CVT after immunization was done by researchers at University College London in order to provide a clearer guide for physicians trying to diagnose and treat such patients.
The study, which was published in The Lancet, is the most comprehensive description of the symptoms of CVT produced by the unique syndrome vaccine-induced immune thrombotic thrombocytopenia (VITT).
Scientists from Oxford’s John Radcliffe Hospital examined the medical records of 70 patients who had VITT-associated CVT after immunization.
These patients were compared to 25 patients who had CVT but no evidence of VITT.
The Expert Hematology Panel has created three therapeutic concepts, according to their research.
These include using non-heparin anticoagulation, offering treatments to try to lower the level of the aberrant antibody implicated in this illness, and avoiding the strategy of giving platelet transfusions to try to get the platelet count back up to normal levels.
Intravenous immunoglobulin, a treatment in which the body is inundated with normal antibodies to try to lessen the effects of the aberrant one, was shown to be the most successful by researchers.
Instead of relying on carers or family members to care for them, many people are able to live independently.
However, despite the fact that this type of seems to be linked to improved outcomes, experts warn against reading too much into the findings of the observational study.
They wish to move forward with a randomized clinical trial to verify their findings.
It comes after the European Medicines Agency (EMA) commissioned a population-based study that indicated that blood clotting events after receiving the AstraZeneca vaccine were the same or less common than those who received the Pfizer mRNA vaccine.
Concerns about blood clotting incidents linked to the AstraZeneca vaccination were reported in March.
The EMA’s safety committee decided a month later that there might be. “Brinkwire Summary News.”